STOCK TITAN

Kynam Capital (CTMX) discloses 15.0M-share, 6.90% stake in CytomX (Schedule 13G/A)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang filed an Amendment No. 1 to a Schedule 13G/A reporting 15,013,093 shares of Common Stock, representing 6.90% of the class.

The filing lists shared voting and dispositive power over the reported 15,013,093 shares. Signatures show the filing was executed on 05/15/2026.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake disclosed: 15,013,093 shares (6.90%).

The filing shows Kynam Capital Management and affiliated entities report beneficial ownership of 15,013,093 shares with shared voting and dispositive power. The ownership is disclosed on an amended Schedule 13G/A, consistent with passive institutional reporting.

Cash‑flow treatment and any trading intentions are not stated; subsequent filings would disclose changes in voting or disposition if they occur.

Filing type Schedule 13G/A (Amendment No. 1) Amendment reporting beneficial ownership
Beneficial ownership 15,013,093 shares Amount reported in Item 4(a)
Percent of class 6.90% Percent reported in Item 4(b)
Beneficially owned regulatory
"Item 4. | Ownership (a) | Amount beneficially owned: 15,013,093"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive power regulatory
"Item 4. | (iv) Shared power to dispose or to direct the disposition of: 15,013,093"
Schedule 13G/A regulatory
"(Amendment No. 1 ) ... Schedule 13G/A reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Kynam Capital report in CTMX?

Kynam Capital and affiliated filers report beneficial ownership of 15,013,093 shares, representing 6.90% of CytomX Therapeutics' common stock. The filing attributes shared voting and dispositive power over those shares to the named filers.

Which entities are named on the Schedule 13G/A for CTMX?

The filing names Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and individual Yue Tang. All three are listed as having shared voting and shared dispositive power over the reported 15,013,093 shares.

When was the Schedule 13G/A amendment signed?

Signatures on the amendment show execution on 05/15/2026. The header of the filing also references 03/31/2026 in the document; the amendment bears the later signature dates.

Does the filing indicate Kynam will sell or buy CTMX shares?

The Schedule 13G/A lists ownership and voting/dispositive power but does not state any intent to buy or sell. The amendment reports current beneficial ownership; trading intentions are not disclosed in the provided excerpt.





23284F105

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Kynam Capital Management, LP
Signature:Yue Tang
Name/Title:Managing Member
Date:05/15/2026
Kynam Capital Management GP, LLC
Signature:Yue Tang
Name/Title:Managing Member
Date:05/15/2026
Yue Tang
Signature:Yue Tang
Name/Title:Self
Date:05/15/2026